InvestorsHub Logo
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: None

Tuesday, 09/21/2010 2:02:27 PM

Tuesday, September 21, 2010 2:02:27 PM

Post# of 4126
CPP-115 Granted Orphan-Drug Designation

"Orphan-drug designation for the treatment of infantile spasms is an important milestone in the development of CPP-115," said Patrick McEnany, Catalyst's Chief Executive Officer. "Currently, there are limited choices available for treating this serious pediatric disease, all of which have significant side effects. We hope to offer providers and their patients a more effective and safer therapy than is currently available."

Catalyst is currently conducting a number of non-clinical safety and efficacy studies with CPP-115 to support various indications and expects to file an IND with respect to CPP-115 in the first half of 2011.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CPRX News